Tagged with Italy

Pharma While the Italian clinical research community works to an excellent standard of quality, and is relatively competitive in terms of costs, regulatory differences with the rest of Europe pose significant challenges. Mariapia Cirenei and Stefano Marini, president of AICRO and EUCROF respectively, discuss these current challenges, and how the new…

Pharma Gnosis is a fully vertically integrated biotech company specialized in the manufacturing and sales of fermentation raw materials and natural finished products used in the pharmaceutical, nutraceutical, cosmetic, veterinary, and agricultural industries. The business development director shares the company’s future plans to strengthen its international footprint. Given your experience, what…

Pharma Charles-Henri Bodin, General Manager of Pierre Fabre, explains how the recent agreement with Pfizer on Toviaz will enlarge their footprint in Italy and how partnerships will play an increasing role in future growth. You’ve been with PF since 1999, serving in various positions in France and Italy before becoming GM…

Pharma Raffaele Stefanelli discusses the challenges of the medtech industry in Italy, the contribution of the Italian research community to Boston Scientific globally, and innovative partnership models. Could you introduce yourself to our readers as you currently hold two positions within Boston Scientific: managing director of the affiliate as well as…

Pharma Samsung is focused on the total digital transformation of medical services. It offers solutions in mobile health, hospital digitalization, and integrated medical and healthcare devices. The head of the healthcare and medical equipment division in Italy Dario Guido discusses how Samsung plans to catalyze a ‘digital transformation’ in Italian healthcare…

Pharma Maurizio Marchesini, CEO of Marchesini Group, discusses the challenges of competing in a very dynamic packaging machinery industry, where their business is differentiated through flexibility and integral service offerings. Further, he talks about how internationalization into developing regions will drive the growth of the group. To begin, could you please…

Pharma Shire Italy’s Francesco Scopesi discusses innovative medicine, rare diseases, growth drivers, global strategy, and the new trend of home care. Shire is today one of the leading biotechs delivering innovative medicines to patients with rare diseases and other specialty conditions. Could you please start by describing the company’s engagement with…

Pharma Long renowned for dancing to a different tune, Italy’s eccentric, but more often than not, enlightened and high performance pharma, healthcare and life sciences community may at last be about to reign in a distinctive penchant for fragmentation. Amongst the myriad of globally recognized luxury brands promulgated by the Italian…

Pharma Doppel has been selected as the nucleus for significant investments in the CDMO industry by PE firm Trilantic Capital Partners, according to recently hired CEO Giuseppe Cassisi, who shares the organization’s plans to invest in both greenfield facilities and M&A in the coming years. Italy’s pharmaceutical exports are growing faster than any other…

Pharma Sergio Liberatore discusses IMS Health Italy’s evolution after the acquisition of Cegedim’s CRM and strategic data businesses and how IMS is paving the way for pharma companies to become more patient-centric. When we last interviewed you in 2009, you were busy reshaping the data-provision branch, strengthening the consultancy capabilities of the business and setting…

Pharma Abramo Brandi, Octapharma Italy’s MD, discusses the challenges of the tender system in Italy and how he has grown the company year-on-year in the midst of a global economic crisis. What are some of your major achievements since becoming Managing Director of Octapharma Italy in 2008? I was asked to…

Pharma Mario Marazziti, President of the Italian XII Social Affairs Commission, discusses new legislation relating to clinical risk, the effects of the 2014 Pact for Health, and the efficiency of Italian healthcare in general. You were recently highly instrumental in the passing of new legislation relating to clinical risk. Could you…